Links are not yet activated.
To activate, add a link back to submitpr.org from your website and contact @jaycosta on Telegram,
or pay via Solana (from $19.95) for instant activation.
Eli Lilly's experimental obesity drug retatrutide produced an average 28.7 percent body weight loss in a major Phase 3 trial, results that match the typical outcomes of bariatric surgery and set a new high-water mark for pharmaceutical weight loss.The TRIUMPH-4 trial data, first announced in December 2025 and now under close scrutiny from regulators and insurers, showed participants on the highest dose shed an average of 71.2 pounds over 68 weeks. Nearly four in ten patients lost 30 percent or more of their body weight.
Retatrutide is the first triple-receptor agonist to reach late-stage clinical testing. Unlike semaglutide, which targets a single receptor, or tirzepatide, which hits two, retatrutide activates three: GLP-1 for appetite suppression, GIP for metabolic regulation, and glucagon for energy expenditure.
The drug emerged from Eli Lilly's peptide engineering program, which began in 2016. Phase 2 results published in the New England Journal of Medicine in June 2023 showed 24.2 percent weight loss, prompting the company to launch eight Phase 3 studies under the TRIUMPH banner.
The obesity drug market has expanded rapidly since semaglutide's approval under the brand name Wegovy. But existing treatments typically deliver 15 to 22 percent weight loss, leaving a gap between medication and surgery that retatrutide now appears to close.
The TRIUMPH-4 trial enrolled patients with obesity and knee osteoarthritis, testing whether weight loss could relieve joint pain alongside metabolic improvements. The results exceeded expectations on both fronts.
Participants on the 12-milligram dose achieved 28.7 percent mean weight loss compared to 2.1 percent for placebo. More than 58 percent of patients lost at least a quarter of their body weight. Pain scores on the standard WOMAC scale dropped 75.8 percent, compared to 40.3 percent in the placebo group. One in eight patients on the drug became entirely free of knee pain.
"These results highlight the powerful effect of retatrutide on body weight, pain and physical function," said Dr. Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health.
Cardiovascular markers also improved. Systolic blood pressure fell 14 millimeters of mercury. Non-HDL cholesterol and triglycerides dropped significantly.
The safety profile carried caveats. Nausea affected 43 percent of patients on the high dose, a rate consistent with other GLP-1 drugs. More notable was dysesthesia, an abnormal touch sensation reported by 20.9 percent of patients at the 12-milligram level, compared to 0.7 percent on placebo. The 18.2 percent discontinuation rate due to adverse events, versus 4 percent for placebo, will draw regulatory attention.
For full coverage, visit https://www.linos.ai/health/retatrutide-phase-3-weight-loss-results/
About Linos NEWS: Linos NEWS (https://www.linos.ai) delivers breaking news and in-depth analysis across politics, technology, business, science, health, world affairs, sports, and entertainment.